Haplo-HSCT in 1 and 2 remissions of AL allows to achieve 10-year OS in 64.7% of children, while the type of acute leukemia does not influence the outcome of haplo-HSCT. The acceptable frequency of development of aGVHD III 0 -IV 0 -18.6% allows to treat haplo-HSCT as therapy in 1 and 2 remissions of high risk group. The main complication of haplo-HSCT is relapse -23.5% in the early posttransplant period to D + 100.
Summary
Haploidentical transplantation (Haplo-HSCT) is an effective method for treating patients with high-risk acute leukemias (AL) who do not have HLA-matched related (MRD) and matched unrelated donors (MUD). During 10 years in R/G/Memorial Institute of children oncology, hematology and transplantation more than 150 patients have Haplo-HSCT. More than 50% of patients were «salvage group» patients. 
Materials and methods

Statistical analysis
SPSS Statistics v.17. Overal survival (OS) was defined as time from study enrollment to death, with living patients censored on the date of the last follow-up. The Kaplan-Meier method was used to estimate OS rates, and the exact log-rank test was used to compare survival curves. Survival estimates are reported with standard errors determined by the method of Peto and Pike.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment option in a number of high-risk oncohematological patients [1] . Availability of HLA-identical siblings or compatible unrelated donors is a common limiting factor for broader allo-HSCT practice, especially among ethnical minorities [2, 3, 4] . Sufficient growth of allo HSCT worldwide activities occurs because of lowering limitations by the stage of diseases, patients' age and comorbidities, due to introduction of fludarabin-containing conditioning regimens (RICs), thus reducing intensity of cytostatic load and transplantation-associated mortality while retaining efficiency and of treatment, along with immunoadoptive effects [5, 6, 7] . Meanwhile, nearly all patients have a potential haploidentical family donor. However, early attempts of haplo-HSCT using a native graft without T cell purging using standard immunosuppression shedules resulted into unacceptable graft-versus-host disease (GVHD) rates whereas ex vivo T cell depletion for GVHD control was accomplished by high risk of non-engraftment and infectious complications causing high mortality [8, 9, 10, 11] . In Russia, approximately 80% of patients requiring allo-HSCT do not have a compatible sibling donor, whereas a chance to find an unrelated donor do not exceed 60-70%, requiring high financial costs, thus presenting the main obstacle for timely performance of allo-HSCT [3] .
Search for alternative stem cell sources, such as umbilical blood cells, or haploidentical donor is quite challenging. To control HSCT risks and to prevent non-engraftment, the workers form Perugia (Italy) have used megadoses of CD34+ cells after their positive selection (a median of >10×10 6 / kg weight), with minimal T cell contamination (a median of 1×10 4 /kg weight) combined with intensive conditioning regimen [11] . This study reported engraftment in 94 of 101 patients with good GVHD control. However, the rates of non-relapse-associated mortality proved to be very high (36.5%) which were largely determined by infections associated with slow immunological recovery. Event-free survival was satisfactory in the patients transplanted in remission, being, however, extremely poor for the patients treated in resistant or relapsing cases. Complexity of this transplantation approach and high costs of the method limited its approval by other transplantation centers.
A group of Chinese workers has used a method avoiding ex vivo T cell depletion based on intensive pre-transplant treatment using myeloablative GIAC conditioning regimens (MAC) combined with anti-thymocyte gobulin as in vivo T cell depletion. The research team used a combined non-manipulated graft containing stimulated peripheral HCSs and bone marrow HSCs. 250 patients with acute leukemias were reported to achieve full donor chimerism, whereas acute and chronic GVHD frequencies were, respectively, 46% and 54%. Despite satisfactory relapse-free survival rates, the standard-risk patients often suffered with opportunistic infections, Transplant-related mortality rates for standard-risk and high-risk groups were, respectively, 19.5% и 29.5% for acute myeloid leukemia (AML), or 21% and 51% for acute lymphoblastic leukemia (ALL) [13] . Another approach to allo-HSCT was developed in Baltimore (USA) included usage of non-manipulated graft followed by post-transplant cyclophosphamide injection (PtCy) to control T cell reactivity after HSCT seems to overcome most obstacles historically connected with haplo-HSCT [14, 22] .
Over last years, the haplo-HSCT methodology has experienced sufficient changes, i.e., novel conditioning protocols were developed with decreased toxicity and low dose intensity; the ex vivo T cell depletion options were designed, i.e., CD34+ cell selection, CD3 + /CD19 + cell depletion, γ/β TCR chain depletion. The in vivo trials, suggest favorable effects from usage of anti-thymocyte globulins (ATG), cyclophosphamide at at high doses on D+3, D+4 after the haploidentical transplant. An immune response modification could be carried out as reduction of T cell reactivity by changing the Th1/Th2 balance, by means of hematopoiesis stimulation with G-CSF before myeloexfusion. Pharmacological prophylaxis of acute GVHD (aGVHD) is accomplished by new therapies, e.g., with rapamycin, the mTOR inhibitor [14, 15, 16] . Good efficiency of haploidentical HSCT is shown for the 1 st and 2 nd remissions of AML, with 5-year relapse-free survival of 82.5%, and 59.4%. Appropriate figures for ALL were 68.9% and 56.6% [15] . The results of relapsed and resistant clinical forms were unsatisfactory if using allo-HSCT, or hapolo-HSC, i.e., the 5-year overall survival in AML was 42.9% and 22.2% in ALL [15, 16, 17, 18] . The aim of our study was to assess efficiency of haplo-HSCT performed with non-manipulated grafts of children and adolescents with high-risk acute leukemias. In this respect an efficiency study of haploidentical GVHD was performed at our clinic in children and adolescents with high-risk ALL and AML, at maximal observation terms of 10 years.
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Patients and methods
The study included 106 children and adolescents 0 to 18 years old (median age, 7 y.o.). with primary diagnosis of ALL in 63 cases (59.4%), and AML (43 patients, 41%), who underwent allo-HSCT from haploidentical donors within a time period of December 2006 to December 2016 года. The patients were followed up for a maximum of 10 years.
Haploidentical HSCT was performed in remission state for 43 patients (40.6%), i.e., 21 patients were transplanted in 1 st remission, 13 patients, in 2 nd remission, and nine children were treated in 3 rd remission. Sixty-three relapsed/ therapy-resistant (R/R) patients with AL were transplanted (59.4% of total). Several MAC schedules were applied for conditioning treatment, i.e., GIAC protocol (39 cases, 36.8% of total) including busulfan (16 mg/kg body weight), cyclophosphamide (Cy) at a dose of 2000 mg/m 2 , cytosar (8000 mg/m 2 ), lomustin (120 mg/kg). Other MACs were based on busulfan (12 mg/kg) and Fludarabin (150 mg/m 2 ), being applied in 2 patients (2%), and a regimen based on Treosulfan (42 g/m 2 ) was used in 6 cases (5.7%). The reduced-intensity conditioning regimens (RICs) based on melphalan (140 mg/ m 2 ) were applied in 40 recipients (37.7%), whereas RICs containing busulfan (8 mg/kg) were used in 18 patients (17%). 
Results
Hematopoiesis recovery
Stem cell engraftment after haplo-HSCT was documented in 80 total group of patients (75.7% of total). Median engraftment term was D+24 (D+14 to D+34). Primary non-engraftment was revealed in 26 patients (24.5%) due to chemoresistance and/or relapsed AL. The median recovery terms for granulocytes (>0.5x10 9 /L) was D+19 (D+10 to D+34); for leukocytes (>1.0x10 9 /L), D+17 (D+10 to D+34); for platelets reconstitution (>20x10 9 /L), D+17 (D+10-D+41). Median recovery time for lymphocytes (>30x10 9 /L) was D+29 (D+14 to D+50). Full donor chimerism was registered in 67 cases (83.8%) by day +30 posttransplant. Thirteen patients (16.2%) developed full chimerism by day +60 after HSCT.
Survival data
Ten-year overall survival (OS) in total group proved to be 33.3% after haplo-HSCT (Fig. 1) . In particular, the ten-year OS in patients transplanted in 1 st and 2 nd remissions was 64.7% as compared to 18.1% for the patients transplanted beyond the remission. (р=0.01; Fig. 2 ). Overall survival for the patients who received G-CSF-primed, non-manipulated bone marrow and in those who got combined marrow/peripheral grafts was, respectively, 38% and 18.5% (р=0.03, Fig.  3 ). The AL type did not influence the 10-year survival, i.e., 
Posttransplant complications
Acute graft-versus-host disease (GVHD) is a major immunological disorder developing early after allo-HSCT. Of 80 patients who achieved engraftment, aGVHD grade II was observed in 21 cases (26.3%); severe GVHD (grade III to IV) was diagnosed in 15 patients (18.6%).
Leukemia relapses were registered in 51 of 106 patients (48.1%), with a mediane of D+91 after haplo-HSCT (D+17 to D+1101). Occurrence of relapses post haplo-HSCT, if performed in 1 st or 2 nd remission was 23.5%, with a median of D+88 (D+30 to D+301). The disease recurrence was more common in recipients with resistant or relapsing disease (56,9%, with a median development on D+81 post-transplant).
The overall transplant-associated mortality was 21.6% in the studied group. Fatal infectious complications in the early post-transplant period were registered in 14 patients (13.2%). Acute GVHD caused death of 7 patients (8.8%), lethal toxic conditions, in 2 cases (1.9%). Meanwhile, the leukemia relapses proved to prevail in post-engraftment lethality among children and adolescents undergoing haplo-HSCT (39 patients, 48.8%). Posttransplant relapses among the patients transplanted in 1 st and 2 nd remissions resulted into lethal outcome in 6 cases (17.6%). Meanwhile, the AL recurrence with lethal outcome was registered in 33 cases (45.8%) among patients who received haploidentical grafts in resistant or relapsing disease upon engraftment.
Discussion
At the present time, HSCT from haploidentical donors is known to be an effective and safe treatment approach for the high-risk leukemia patients, requiring allo-HSCT for urgent reasons, especially in absence of a compatible donors, either related or unrelated ones. Fast preparation of a donor and HSC isolation, good chances for repeated graft harvest if required, as well as minimal financial costs comprise clear benefits of haplo-HSCT. However, some cautions exist, due to risks of posttransplant complications, such as acute GVHD and severe infections determined by marked immunosuppression and prolonged immune recovery after haplo-HSCT. Moreover, a specific graft-versus-leukemia (GvL) response after haplo-HSCT and persistence of this effect is still in question, being subject to different studies [20] . Application of RIC regimens as a platform for the post-transplant immunonadoptive therapy may provide an additional tool for enhancement of the GvL immune reaction without increasing the transplant-related mortality.
Some promising data on the subject are published by a study team at the John Hopkins and Fred Hutchinson Cancer Research Center on the patients with high-risk acute leukemia who underwent reduced-intensity conditioning followed by haplo-HSCT and post-transplant cyclophosphamide injections on D+3 and D+4. According to this study, clinical engraftment was registered in 87% of the cases, with OS values of 41%. Clinically sound aGHVD (grade II-IV) was registered in <27%, with chronic GVHD documented in 15% of the cases. However, frequency of post-transplant relapses remained high (55%), with relatively low transplant-related mortality (18%) [20, 22] .
Our own data on haplo-HSCT confirm the high rates of transplant engraftment (80%), while reaching full donor chimerism by day+30 in 84% of the cases. The rest of this group developed full chimerism by day +60 post-HSCT. Overall survival with a maximal observation term of 10 years was 33.3% for the total group. Frequency of clinical aGVHD in our study is also comparable to the previously reported data,
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i.e., prevalence of aGVHD grade II was 26.3%, aGVHD grade III-IV, 18.6%, which does not exceed the published values [20] . We have obtained encouraging results on the 10-year overall survival (64.7%) for the haplo-HSCT patients who received their graft during 1 st and 2 nd remissions. Absence of severe lethal infectious complications before D+100 seems to be connected with faster T cell reconstitution.
Post-transplant relapses represent the main problem for these patients. High percentage of such dismal outcomes (48.1%) may be explained by the disease status at the time of haplo-HSCT. The majority of patients (72 cases, 68%) were transplanted beyond the registered remission. According to the data published by Italian workers, the relapse rates may reach 50% in such patient groups [7, 12] .
Conclusion
Allo-HSCT of the non-manipulated primed bone marrow from a haploidentical donor proved to be an effective approach, in order to achieve clinical remission in children and adolescents with high-risk AL. At the present time, one may discuss relative benefits of different stem cell separation techniques for haplo-HSCT in childhood. Implementation of post-transplant cyclophosphamide (PtCy) proved to be an available and effective regimen improving clinical results of haplo-HSCT. State of the disease is the main factor influencing overall survival after haplo-HSCT. First or second remission of ALL or AML is the optimal time-point for haplo-HSCT. To improve the results of haplo-HSCT in Russia, the appropriate cooperative multicentric studies are required in this research area.
